Randomized trial · people
Tirzepatide beat semaglutide 1 mg on HbA1c at 40 weeks in SURPASS-2
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a direct comparison with semaglutide 1 mg, all three tirzepatide doses lowered HbA1c and body weight more, and stomach side effects were the most common complaint with both drugs.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1879
- Published
- 2021
- Journal
- N Engl J Med
What they tested
The team wanted to know whether once-weekly tirzepatide lowers blood sugar at least as well as, or better than, once-weekly semaglutide in people with type 2 diabetes.
How the study was done
An open-label (everyone knew which drug they got), randomized, phase 3 trial that split 1879 patients with type 2 diabetes evenly into tirzepatide 5 mg, 10 mg or 15 mg arms or a semaglutide 1 mg arm for 40 weeks. Participants were 56.6 years old and weighed 93.7 kg on average, and their HbA1c (a 3-month average of blood sugar) averaged 8.28% when the trial began.

Model. Individual results vary.
What they found
HbA1c fell by an estimated 2.01, 2.24 and 2.30 percentage points in the 5 mg, 10 mg and 15 mg tirzepatide arms, compared with 1.86 points in the semaglutide arm. Next to semaglutide, the extra drop was 0.15, 0.39 and 0.45 points, so every tirzepatide dose was both noninferior (no worse) and superior. Weight loss was also greater with tirzepatide, by an estimated 1.9 kg, 3.6 kg and 5.5 kg across the three doses. Stomach side effects were the most common and mostly mild to moderate, with nausea in 17 to 22% on tirzepatide and 18% on semaglutide; low blood sugar under 54 mg per deciliter was reported in 0.2% to 1.7% on tirzepatide and 0.4% on semaglutide, and serious adverse events in 5 to 7% on tirzepatide and 3% on semaglutide.
What it doesn’t show
Patients and doctors knew which drug was given, the trial ran 40 weeks, and tirzepatide was compared only with semaglutide at 1 mg. The trial was funded by Eli Lilly.
The paper
Frías et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021.
The compounds
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeksRandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.